Furthermore, it has been previously demonstrated that the enforced expression of miR-29c enhances cisplatin sensitivity in lung cancer cells by targeting AKT2, while the silencing of miR-29c promotes cisplatin resistance in cancer cells by activating the PI3K/Akt pathway. This evidence concerns the gene AKT1 and lung cancer.